Managers / Q2 2024 · view latest →
Checkpoint Capital L.P.
CIK 0001977548 · 345 CALIFORNIA STREET, SUITE 600, SAN FRANCISCO, CA, 94104 · 914-355-0570
Summary
Checkpoint Capital L.P. reported $166M in U.S.-listed holdings across 16 positions for Q2 2024.
The portfolio is heavily concentrated: RYTM alone accounts for 22.8% of reported value.
Compared with Q1 2024, the fund opened 5 new positions and exited 6.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 69.1% · $115M
- ADR · 21.3% · $35M
- Other · 9.6% · $16M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AVADEL PHARMACEUTICALS PLC | NEW | +1.14M | 1.14M | +$16M | $16M |
| PLRXPLIANT THERAPEUTICS INC | NEW | +232.2K | 232.2K | +$2M | $2M |
| KYMRKYMERA THERAPEUTICS INC | NEW | +82.0K | 82.0K | +$2M | $2M |
| CDTXCIDARA THERAPEUTICS INC | NEW | +145.4K | 145.4K | +$2M | $2M |
| SLNOEURSOLENO THERAPEUTICS INC | NEW | +19.7K | 19.7K | +$803,556 | $803,556 |
| AXSMAXSOME THERAPEUTICS INC | ADDED | +158.3K | 290.8K | +$13M | $23M |
| AVADEL PHARMACEUTICALS PLC | SOLD OUT | −701.4K | 0 | −$12M | $0 |
| MIRMMIRUM PHARMACEUTICALS INC | SOLD OUT | −362.2K | 0 | −$9M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RYTMRHYTHM PHARMACEUTICALS INChistory → | COM | 22.82% | $38M | 922.1K |
| 2 | ARGXARGENX SEhistory → | SPONSORED ADR | 21.30% | $35M | 82.2K |
| 3 | AXSMAXSOME THERAPEUTICS INChistory → | COM | 14.11% | $23M | 290.8K |
| 4 | AVADEL PHARMACEUTICALS PLC | COM SHS | 9.65% | $16M | 1.14M |
| 5 | PTGXPROTAGONIST THERAPEUTICS INChistory → | COM | 7.42% | $12M | 355.0K |
| 6 | CYTKCYTOKINETICS INChistory → | COM NEW | 6.21% | $10M | 190.0K |
| 7 | PHATPHATHOM PHARMACEUTICALS INChistory → | COM | 5.43% | $9M | 875.0K |
| 8 | HTDCORCEPT THERAPEUTICS INChistory → | COM | 4.79% | $8M | 244.8K |
| 9 | ATYRATYR PHARMA INChistory → | COM NEW | 1.83% | $3M | 1.95M |
| 10 | PLRXPLIANT THERAPEUTICS INChistory → | COM | 1.50% | $2M | 232.2K |
| 11 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 1.48% | $2M | 82.0K |
| 12 | CDTXCIDARA THERAPEUTICS INChistory → | COM NEW | 1.05% | $2M | 145.4K |
| 13 | TRVITREVI THERAPEUTICS INC | COM | 0.90% | $1M | 500.1K |
| 14 | APLTAPPLIED THERAPEUTICS INC | COM | 0.64% | $1M | 227.5K |
| 15 | SLNOEURSOLENO THERAPEUTICS INC | COM | 0.48% | $803,556 | 19.7K |
| 16 | ALLKGUSDALLAKOS INC | COM | 0.39% | $649,957 | 650.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $279M | 8 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $320M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $298M | 10 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $215M | 8 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $182M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $196M | 16 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $202M | 16 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $166M | 16 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $150M | 17 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $165M | 19 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.